What is Leadoptik?
Headquartered in San Jose, California, Leadoptik is a pioneering deep-tech startup focused on the intersection of advanced optics and medical intervention. The company specializes in the development of miniature imaging platforms designed to provide surgeons with unprecedented visibility during minimally invasive procedures. By integrating real-time 3D navigation capabilities, Leadoptik addresses critical gaps in current surgical workflows, offering a solution that enhances precision and patient outcomes. The company's technology is engineered to operate within the constraints of small-scale medical devices, effectively miniaturizing high-resolution imaging systems that were previously restricted to larger, less agile equipment. This innovation places Leadoptik at the forefront of the next generation of surgical robotics and diagnostic tools.
How much funding has Leadoptik raised?
Leadoptik has raised a total of $9.6M across 2 funding rounds:
Angel/Seed
$5M
Stock/Share Issuance
$4.6M
Angel/Seed (2023): $5M with participation from Tsvc, Sony Innovation Fund, MetaVC Partners, and SOSV
Stock/Share Issuance (2025): $4.6M, investors not publicly disclosed
Key Investors in Leadoptik
Tsvc
TSVC is a venture capital firm that specializes in investing in deep tech and physical AI startups, particularly those founded by immigrant entrepreneurs.
Sony Innovation Fund
Sony Innovation Fund is dedicated to engaging with innovative stage startups to help fuel development of disruptive technologies and launch of new businesses.
SOSV
SOSV is a multi-stage venture capital investor that provides intellectual and financial capital to accelerate founders big ideas.
What's next for Leadoptik?
With the recent influx of capital, Leadoptik is poised to transition from its current development phase toward broader clinical validation and commercial scaling. The strategic focus will likely center on refining its 3D navigation software and expanding its intellectual property portfolio to maintain a competitive edge in the medical technology landscape. Furthermore, the company is expected to leverage its partnerships with key institutional investors to navigate regulatory pathways and establish a robust supply chain for its imaging components. As the firm moves forward, the emphasis will remain on demonstrating the clinical efficacy of its platform, thereby paving the way for widespread adoption in hospitals and surgical centers globally.
See full Leadoptik company page
